Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)

E Hamilton,A Conlin,V Borges,L Walker,S Moulder

doi:10.1158/1538-7445.sabcs16-p4-21-01

Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)

E Hamilton, A Conlin + Show 3 more

https://doi.org/10.1158/1538-7445.sabcs16-p4-21-01

Copy DOI

Journal: American Journal of Cancer	Publication Date: Feb 14, 2017
Citations: 6

Affiliation: University of Colorado Cancer Center

#Prior Lapatinib #Brain Mets + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)

Full Text